Exscientia

Biotech & Life Sciences · Oxford, United Kingdom · Founded 2012 · IPO 2021

Applying artificial intelligence and big data processing to accelerate discovery and development of drugs

Valuation $500M–1B

Revenue $10–50M

Headcount <100

Unlock exact values

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Featured in

Market map Computational Biology & Chemistry startups in Europe

Investors

18 investors on Exscientia's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

Evotec

Series B+ 17 investors entered at this stage

BlackRock

Laurion Capital Management

Celgene

Novo Seeds

Bristol-Myers Squibb

Mubadala Capital

Casdin Capital

SoftBank

Novo Holdings

Frontier IP Group

University of Dundee

SoftBank Vision Fund

Marshall Wace

Farallon Capital Management

Pivotal Life Sciences

GT Technologies

GT Healthcare

Exscientia mafia

Startups founded by Exscientia alumni

Former Exscientia employees who went on to start their own companies. Sorted by Dealroom signal score.

Myricx BioEst. 2019

Andrew BellUnited Kingdom

Signal score92

Graph TherapeuticsEst. 2024

Gregory VladimerAustria

Signal score77

Outpost BioEst. 2025

JYJenny YangUnited States

Signal score70

CHARM TherapeuticsEst. 2021

Laksh AithaniUnited Kingdom

Signal score63

Affinia TherapeuticsEst. 2019

Rob Johnson.United States

Signal score62

DaltontxEst. 2024

ARAdrian RossallUnited Kingdom

Signal score51

Book a demo to explore the full alumni network →

Global footprint

Where Exscientia has talent and traffic

Workforce by country

9 countries with
team presence

🇬🇧 United Kingdom64.2%

🇦🇹 Austria20.2%

🇸🇪 Sweden4%

🇨🇭 Switzerland2.3%

🇩🇪 Germany2.2%

Top 5 of 9 shown

Web traffic by country

490 monthly visits
across markets

🇯🇵 Japan81.6%

🇺🇸 United States0%

Top 2 markets shown

Talent graph

The shape of Exscientia's talent

Dealroom maps Exscientia's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

12 standout operatorsDealroom-flagged across the org

9 AI specialistsincl. 5 core researchers

44 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Exscientia's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$9M patent portfolio · 16 active families

Estimated portfolio value

$9M

1.3% of valuation · 53× smaller than top peer Genmab ($488M)

16 active patent families

Where Exscientia innovates Chemical compoundAmideBiochemistryBiological organismBiology cell

Where Exscientia concentrates vs peers

Each axis is a top-10 topic across Exscientia and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Exscientia

An AI-synthesized read of the highest-engagement posts about Exscientia on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Exscientia on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles